Jason Carey, Senior Medical Science Liaison at GRAIL, shared a post on LinkedIn:
“ASCO 2025 Spotlight: Early Detection is Changing the Game
This year’s ASCO meeting made one thing crystal clear: multi-cancer early detection (MCED) is no longer a futuristic concept – it’s here, and it’s impacting lives.
Here are some of the most impactful updates on cancer screening and early detection:
1. GRAIL’s CCGA Study – 5-Year Follow-Up Data
– GRAIL presented powerful follow-up data from its Circulating Cell-free Genome Atlas (CCGA) study.
– The test continues to show preferential detection of high-grade, clinically significant cancers—including aggressive prostate cancers—while reducing the risk of overdiagnosing indolent disease.Bottom line: Earlier detection => better long-term survival.
2. Dana-Farber’s Real-World MCED Experience
– Dana-Farber shared real-world data on MCED test implementation.
– Their analysis showed clinical utility and outcomes of integrating MCED into routine practice.
– Real data. Real patients. Real potential.3. MCED Screening Interval Modeling
Should we screen annually or every other year?
Modeling shows:– Annual MCED screening could reduce late-stage diagnoses by 43%
– And cut cancer-related deaths by 16% over 5 years
– A powerful complement to existing guideline-based screening.Takeaway:
Early detection isn’t just a buzzword. The data proves we can intervene earlier, save more lives, and change the cancer care continuum.”
Read OncoDaily’s Special Articles from ASCO25:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
